A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation

PHASE2CompletedINTERVENTIONAL
Enrollment

526

Participants

Timeline

Start Date

October 8, 2009

Primary Completion Date

March 6, 2012

Study Completion Date

March 6, 2012

Conditions
Acute Coronary Syndrome
Interventions
DRUG

GW856553

7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID

DRUG

GW856553

15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID

DRUG

Placebo

Placebo

Trial Locations (108)

2170

GSK Investigational Site, Liverpool

2217

GSK Investigational Site, Kogarah

4032

GSK Investigational Site, Brisbane

5011

GSK Investigational Site, Woodville South

5042

GSK Investigational Site, Bedford Park

6000

GSK Investigational Site, Perth

6160

GSK Investigational Site, Fremantle

7250

GSK Investigational Site, Launceston

10117

GSK Investigational Site, Berlin

10249

GSK Investigational Site, Berlin

11047

GSK Investigational Site, Jerez (Cadiz)

11215

GSK Investigational Site, Brooklyn

11794

GSK Investigational Site, Stony Brook

13353

GSK Investigational Site, Berlin

13509

GSK Investigational Site, Berlin

14165

GSK Investigational Site, Berlin

14467

GSK Investigational Site, Potsdam

15706

GSK Investigational Site, Santiago de Compostela

17011

GSK Investigational Site, Camp Hill

18103

GSK Investigational Site, Allentown

19141

GSK Investigational Site, Philadelphia

20099

GSK Investigational Site, Hamburg

22291

GSK Investigational Site, Hamburg

26133

GSK Investigational Site, Oldenburg

27610

GSK Investigational Site, Raleigh

27710

GSK Investigational Site, Durham

29010

GSK Investigational Site, Málaga

30322

GSK Investigational Site, Atlanta

30625

GSK Investigational Site, Hanover

32209

GSK Investigational Site, Jacksonville

33604

GSK Investigational Site, Bielefeld

33701

GSK Investigational Site, St. Petersburg

36043

GSK Investigational Site, Fulda

37075

GSK Investigational Site, Göttingen

37830

GSK Investigational Site, Oak Ridge

37917

GSK Investigational Site, Knoxville

39120

GSK Investigational Site, Magdeburg

41464

GSK Investigational Site, Neuss

42117

GSK Investigational Site, Wuppertal

44035

GSK Investigational Site, Elyria

44137

GSK Investigational Site, Dortmund

45138

GSK Investigational Site, Essen

46290

GSK Investigational Site, Indianapolis

51109

GSK Investigational Site, Cologne

51375

GSK Investigational Site, Leverkusen

52074

GSK Investigational Site, Aachen

52242

GSK Investigational Site, Iowa City

53127

GSK Investigational Site, Bonn

55407

GSK Investigational Site, Minneapolis

55905

GSK Investigational Site, Rochester

57701

GSK Investigational Site, Rapid City

60590

GSK Investigational Site, Frankfurt am Main

60612

GSK Investigational Site, Chicago

61231

GSK Investigational Site, Bad Nauheim

64283

GSK Investigational Site, Darmstadt

65549

GSK Investigational Site, Limburg an der Lahn

67550

GSK Investigational Site, Worms

68167

GSK Investigational Site, Mannheim

75216

GSK Investigational Site, Dallas

76104

GSK Investigational Site, Fort Worth

76437

GSK Investigational Site, Rastatt

77901

GSK Investigational Site, Victoria

78681

GSK Investigational Site, Round Rock

78756

GSK Investigational Site, Austin

79106

GSK Investigational Site, Amarillo

79189

GSK Investigational Site, Bad Krozingen

85724

GSK Investigational Site, Tucson

89081

GSK Investigational Site, Ulm

90033

GSK Investigational Site, Los Angeles

92691

GSK Investigational Site, Mission Viejo

99089

GSK Investigational Site, Erfurt

99437

GSK Investigational Site, Bad Berka

99508

GSK Investigational Site, Anchorage

380060

GSK Investigational Site, Ahmedabad

411004

GSK Investigational Site, Pune

560052

GSK Investigational Site, Bangalore

560054

GSK Investigational Site, Bangalore

560099

GSK Investigational Site, Bangalore

673002

GSK Investigational Site, Calicut

40536-0284

GSK Investigational Site, Lexington

T2N 2T9

GSK Investigational Site, Calgary

H1T 1C8

GSK Investigational Site, Montreal

G1V 4G5

GSK Investigational Site, Sainte-Foy

J6V 2H2

GSK Investigational Site, Terrebonne

01307

GSK Investigational Site, Dresden

04289

GSK Investigational Site, Leipzig

01796

GSK Investigational Site, Pirna

06120

GSK Investigational Site, Halle

1091 AC

GSK Investigational Site, Amsterdam

1105 AZ

GSK Investigational Site, Amsterdam

6815 AD

GSK Investigational Site, Arnhem

3435 CM

GSK Investigational Site, Nieuwegein

5022 GC

GSK Investigational Site, Tilburg

30-901

GSK Investigational Site, Krakow

31-501

GSK Investigational Site, Krakow

Unknown

GSK Investigational Site, Krakow

26-617

GSK Investigational Site, Radom

04-628

GSK Investigational Site, Warsaw

03010

GSK Investigational Site, Alicante

08907

GSK Investigational Site, Barcelona

BN2 5BE

GSK Investigational Site, Brighton, East Sussex

BS2 8HW

GSK Investigational Site, Bristol

G81 4HX

GSK Investigational Site, Clydebank

EH16 4SA

GSK Investigational Site, Edinburgh

LE3 9QP

GSK Investigational Site, Leicester

SE1 7EH

GSK Investigational Site, London

SE5 9RS

GSK Investigational Site, London

W2 1NY

GSK Investigational Site, Paddington, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00910962 - A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation | Biotech Hunter | Biotech Hunter